Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact

Clinical Pathways

Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact
July 8, 2025
Guest User
New Final Guidance Q&A on RRAs

07/08/2025

-

In June 2025, The US Food and Drug Administration (FDA) released the final guidance titled; “Conducting Remote Regulatory Assessments Questions and Answers” to facilitate understanding about what a remote regulatory assessment (RRA) is expected from establishments when the FDA initiates or requests an RRA.

New Final Guidance Q&A on RRAs
June 23, 2025
Guest User
BIMO Finds Objectionable Conditions During ...

06/23/2025

-

On June 5, 2025, the US Food and Drug Administration (FDA) issued a warning letter and FDA Form 483 to an investigator as a result of objectional conditions observed during a Bioresearch Monitoring Program (BIMO) inspection. According to the letter, the investigator did not adhere to the applicable statutory requirements of Title 21 CFR part 312.60 which states: “An investigator is responsible for ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations”.

BIMO Finds Objectionable Conditions During Inspection
June 17, 2025
Guest User
FDA shares FAQs on IRBs

06/17/2025

-

In February 2025 the US Food and Drug Administration (FDA) posted a series of frequently asked questions (FAQ) on their website from the public regarding Institutional Review Boards (IRB) and the protection of human subjects in research.

FDA shares FAQs on IRBs
June 3, 2025
Guest User
Final Guidance Released on IRB Written ...

06/03/2025

-

In February 2025, the US Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) Office for Human Research Protection (OHRP) released the final guidance “Institutional Review Board (IRB) Written Procedures.”

Final Guidance Released on IRB Written Procedures
May 30, 2025
Guest User
Now Available: Clinical Pathways’ Major Changes ...

05/30/2025

-

In the ever changing world of clinical research, staying up to date with the latest guidelines and best practices is crucial. Our Major Changes in GCP from ICH E6(R2) to (R3): Road Map is designed for busy professionals who want to deepen their knowledge on GCP to help ensure they meet the highest standards of quality, safety, and compliance.

Sandra Sather
June 24, 2015

Electronic Informed Consent / August 10th

Sandra Sather
June 24, 2015

06/24/2015

For those that manage clinical trials, collecting informed consent through traditional paper-based methods is quickly becoming outdated. Electronic media offers many advantages for both patients and the advancement of scientific research.

Sandra Sather
June 19, 2015

New Technology for Remote Monitoring! Event Monday June 22nd 6:30pm

Sandra Sather
June 19, 2015

06/19/2015

Promeditec has developed a package that enables the user to carry out remote monitoring of clinical trials. Virtual On Site Monitoring (VOS) integrates high-cost traditional monitoring with an innovative method that leads to significant reduction in time and cost by eliminating the need for monitor relocation. 

Sandra Sather
June 2, 2015

The Modern Risk Based Monitor! Sing Along.

Sandra Sather
June 2, 2015

06/02/2015

Thank you, Laurie Meehan!

Sandra Sather
May 16, 2015

REMOTE Source Data Review and Verification: WHY NOT?

Sandra Sather
May 16, 2015

05/16/2015

Monitoring clinical data is a critical part of trial success. Part of doing this effectively is efficiency, so a question being asked more frequently is “why not monitor source data remotely?” This course discusses the feasibility of remote monitoring of source data in compliance with predicate rules, including HIPAA, FDA, as well as mandates outside the US.

Sandra Sather
May 13, 2015

New Sponsor-Investigator WL

Sandra Sather
May 13, 2015

05/13/2015

There's a new FDA Warning Letter recently posted for a Sponsor-Investigator. Get access and learn about what this means for clinical research!

Newer Posts
Older Posts
 
Archive List
  • 2013 6
  • 2014 31
  • 2015 25
  • 2016 21
  • 2017 31
  • 2018 55
  • 2019 56
  • 2020 63
  • 2021 50
  • 2022 39
  • 2023 27
  • 2024 25
  • 2025 20

Subscribe to Blogs and Newsletters.

By signing up, you agree to our our Privacy Policy. You may unsubscribe from emails at any time.

Thank you! You will receive a confirmation email shortly.

Back to Top
Clinical Pathwaysinfo@clinicalpathwaysresearch.com

Cookie Notice | License Agreement | Privacy Policy | Return Policy | Terms and Conditions | Data Security Policy | Confidentiality Policy

© 2025 Clinical Pathways. All rights reserved.